Novel Derivatives of Docosahexaenoylethanolamide as Therapeutics for Neuronal Disorders
Lead Inventor: Juan Marugan (NCATS)
Inventors: Erika Englund (NCATS), Hee-Yong Kim (NIAAA), Samarjit Patnaik (NCATS)
Ref. No.: E-070-2012/0
Abstract: This technology provides derivatives of Docosahexaenoylethanolamide (synaptamide or DEA) which have increased potency and hydrolysis resistance as compared to DEA (structures of these derivatives are available upon request), as well as methods of using these derivatives to promote neurogenesis, neurite growth, and/or synaptogenesis. Docosahexaenoic acid (DHA), an n-3 polyunsaturated fatty acid that accumulates in the brain during development, has been shown to play a key role in learning and memory development. Studies have also shown that DEA, a metabolite derived from DHA is very potent in accelerating neuronal growth and development. The inventors have discovered that the novel DEA derivatives they have designed are even more potent than DEA or DHA in accelerating neuronal growth, synaptogenesis and development. The inventors have shown that treatment of progenitor neural cells with some of these novel DEA derivatives leads to an increase in the amount of somatic neurons produced after differentiation. These novel compounds can be developed as therapeutics for conditions such as trauma, stroke, multiple sclerosis, Alzheimer's disease, brain and spinal cord injuries, and peripheral nerve injuries for rehabilitation.
A Synaptogenic Amide N-docosahexaenoylethanolamide Promotes Hippocampal Development • Prostaglandins & Other Lipid Mediators • November 2011 • Probe Development Branch, NCATS Chemical Genomics Center
N-Docosahexaenoylethanolamide Promotes Development of Hippocampal Neurons • Biochemical Journal • April 15, 2011 • Probe Development Branch, NCATS Chemical Genomics Center
Docosahexaenoic Acid Promotes Hippocampal Neuronal Development and Synaptic Function • Journal of Neurochemistry • October 2009 • Probe Development Branch, NCATS Chemical Genomics Center